Y

Yantai Dongcheng Biochemicals Co Ltd
SZSE:002675

Watchlist Manager
Yantai Dongcheng Biochemicals Co Ltd
SZSE:002675
Watchlist
Price: 12.32 CNY -1.91%
Market Cap: 10.2B CNY
Have any thoughts about
Yantai Dongcheng Biochemicals Co Ltd?
Write Note

Yantai Dongcheng Biochemicals Co Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Yantai Dongcheng Biochemicals Co Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Y
Yantai Dongcheng Biochemicals Co Ltd
SZSE:002675
Cash & Cash Equivalents
ÂĄ847.7m
CAGR 3-Years
11%
CAGR 5-Years
9%
CAGR 10-Years
20%
Beigene Ltd
HKEX:6160
Cash & Cash Equivalents
ÂĄ15B
CAGR 3-Years
33%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Cash & Cash Equivalents
ÂĄ9.2B
CAGR 3-Years
27%
CAGR 5-Years
62%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash & Cash Equivalents
ÂĄ3.8B
CAGR 3-Years
75%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cash & Cash Equivalents
ÂĄ5.6B
CAGR 3-Years
9%
CAGR 5-Years
38%
CAGR 10-Years
20%
Imeik Technology Development Co Ltd
SZSE:300896
Cash & Cash Equivalents
ÂĄ2.4B
CAGR 3-Years
-11%
CAGR 5-Years
56%
CAGR 10-Years
N/A
No Stocks Found

Yantai Dongcheng Biochemicals Co Ltd
Glance View

Market Cap
10.2B CNY
Industry
Biotechnology

In the bustling industrial city of Yantai, nestled along China's northeastern coast, Yantai Dongcheng Biochemicals Co Ltd has emerged as a formidable entity in the global biopharmaceutical landscape. Founded in 1998, the company has cleverly positioned itself at the confluence of modern science and traditional Chinese medicine. The hallmark of Dongcheng's business is its sophisticated production of active pharmaceutical ingredients (APIs), particularly heparin, which has earned it a prominent spot on the world stage. Through its agile manufacturing processes and commitment to quality, the company deftly navigates the intricate web of pharmaceutical demands, supplying essential components to global drug manufacturers who trust Dongcheng's expertise to ensure efficacy and safety in their final products. The financial engine of Yantai Dongcheng Biochemicals is powered by its vertically integrated model, which extends from raw material acquisition to finished product delivery. This strategic structure not only mitigates costs and enhances supply chain stability but also fortifies its competitive edge in the burgeoning healthcare market. The company has also expanded its portfolio to include a diverse array of biochemical products, catering to various therapeutic areas such as anticoagulation, oncology, and anti-infectives. This diversification not only spreads risk but also captures a broader spectrum of revenue opportunities. Moreover, Dongcheng's keen eye for innovation has seen it invest heavily in research and development, ensuring that it remains at the cutting edge of biopharmaceutical advancements. Through this strategic orchestration of resources and innovation, Dongcheng continues to deepen its footprint in the global market, underscoring its reputation as a trusted and dynamic player in the pharmaceutical industry.

Intrinsic Value
18.38 CNY
Undervaluation 33%
Intrinsic Value
Price
Y

See Also

What is Yantai Dongcheng Biochemicals Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
847.7m CNY

Based on the financial report for Sep 30, 2024, Yantai Dongcheng Biochemicals Co Ltd's Cash & Cash Equivalents amounts to 847.7m CNY.

What is Yantai Dongcheng Biochemicals Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
20%

Over the last year, the Cash & Cash Equivalents growth was -47%. The average annual Cash & Cash Equivalents growth rates for Yantai Dongcheng Biochemicals Co Ltd have been 11% over the past three years , 9% over the past five years , and 20% over the past ten years .

Back to Top